看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -76.5x - -84.5x | -80.5x |
| Selected Fwd EBIT Multiple | 4.2x - 4.7x | 4.5x |
| Fair Value | ₩44,342 - ₩48,915 | ₩46,629 |
| Upside | 13.3% - 24.9% | 19.1% |
| Benchmarks | Ticker | Full Ticker |
| Oscotec Inc. | A039200 | KOSDAQ:A039200 |
| Komipharm International Co., Ltd. | A041960 | KOSDAQ:A041960 |
| Hanall Biopharma Co., Ltd. | A009420 | KOSE:A009420 |
| ADBiotech Co., Ltd. | A179530 | KOSDAQ:A179530 |
| WooGene B&G Co., Ltd | A018620 | KOSDAQ:A018620 |
| Mezzion Pharma Co.,Ltd. | A140410 | KOSDAQ:A140410 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| A039200 | A041960 | A009420 | A179530 | A018620 | A140410 | ||
| KOSDAQ:A039200 | KOSDAQ:A041960 | KOSE:A009420 | KOSDAQ:A179530 | KOSDAQ:A018620 | KOSDAQ:A140410 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | -57.7% | NM- | -34.7% | NM- | |
| 3Y CAGR | NM- | NM- | -71.6% | NM- | -3.4% | NM- | |
| Latest Twelve Months | 91.6% | 198.7% | -86.8% | 13.7% | -66.3% | 1.3% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -375.3% | -9.1% | 4.8% | -36.8% | 1.9% | -70.2% | |
| Prior Fiscal Year | -659.6% | -14.7% | 1.3% | -45.6% | 1.2% | -45.7% | |
| Latest Fiscal Year | -8.0% | 10.5% | 0.2% | -37.0% | 0.4% | -166.0% | |
| Latest Twelve Months | -8.0% | 10.5% | 0.2% | -37.0% | 0.4% | -166.0% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 28.28x | 7.36x | 9.81x | 2.57x | 1.29x | 133.28x | |
| EV / LTM EBITDA | -1209.6x | 46.6x | 406.9x | -9.2x | 17.3x | -86.0x | |
| EV / LTM EBIT | -351.8x | 69.9x | 5915.9x | -6.9x | 298.6x | -80.3x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -351.8x | 69.9x | 5915.9x | ||||
| Historical EV / LTM EBIT | -638.0x | -66.5x | -15.0x | ||||
| Selected EV / LTM EBIT | -76.5x | -80.5x | -84.5x | ||||
| (x) LTM EBIT | (14,300) | (14,300) | (14,300) | ||||
| (=) Implied Enterprise Value | 1,093,529 | 1,151,083 | 1,208,638 | ||||
| (-) Non-shareholder Claims * | 27,004 | 27,004 | 27,004 | ||||
| (=) Equity Value | 1,120,533 | 1,178,087 | 1,235,642 | ||||
| (/) Shares Outstanding | 30.0 | 30.0 | 30.0 | ||||
| Implied Value Range | 37,341.97 | 39,259.98 | 41,177.98 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 37,341.97 | 39,259.98 | 41,177.98 | 39,150.00 | |||
| Upside / (Downside) | -4.6% | 0.3% | 5.2% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A039200 | A041960 | A009420 | A179530 | A018620 | A140410 | |
| Enterprise Value | 961,777 | 431,638 | 1,363,476 | 28,569 | 71,870 | 1,147,783 | |
| (+) Cash & Short Term Investments | 102,728 | 22,448 | 24,706 | 1,679 | 20,778 | 28,617 | |
| (+) Investments & Other | 2 | 1,010 | 44,134 | 1,923 | 6,082 | 3 | |
| (-) Debt | (13,816) | (43,839) | (1,448) | (11,722) | (31,658) | (1,616) | |
| (-) Other Liabilities | (4,604) | (3,257) | 0 | 1,862 | (41,622) | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | (1,796) | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 1,046,088 | 407,999 | 1,430,869 | 20,515 | 25,450 | 1,174,787 | |
| (/) Shares Outstanding | 38.2 | 69.7 | 50.7 | 11.4 | 28.9 | 30.0 | |
| Implied Stock Price | 27,350.00 | 5,850.00 | 28,200.00 | 1,806.00 | 881.00 | 39,150.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 27,350.00 | 5,850.00 | 28,200.00 | 1,806.00 | 881.00 | 39,150.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |